Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on role of response predictors

Coppola, Nicola; Pisaturo, M.; Sagnelli, Caterina; Angelillo, IF

doi:10.1016/j.dld.2014.01.045

Cited by 9 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For many years, pegylated interferon alpha (IFN) plus ribavirin (RBV) combination therapy was the standard treatment for HCV infection . This combination therapy provided a sustained clearance of circulating HCV (sustained viral response—SVR) in half of the patients infected with HCV‐genotype 1, in around 70% of those with HCV‐genotype 2 and around 60% of those with HCV‐genotype 3; however, the frequency and severity of the side‐effects (flu‐like symptoms, depression, cytopenia, and hemolytic anemia) made this therapy burdensome for many patients …”

Section: Introductionmentioning

confidence: 99%

Virological patterns of HCV patients with failure to interferon‐free regimens

Starace

Minichini

Pascalis

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

The study characterized the virological patterns and the resistance-associated substitutions (RASs) in patients with failure to IFN-free regimens enrolled in the real-life setting. All 87 consecutive HCV patients with failed IFN-free regimens, observed at the laboratory of the University of Campania, were enrolled. All patients had been treated with DAA regimens according to the HCV genotype, international guidelines, and local availability. Sanger sequencing of NS3, NS5A, and NS5B regions was performed at failure by home-made protocols. Of the 87 patients enrolled, 13 (14.9%) showed a misclassified HCV genotype, probably causing DAA failure, 16 had been treated with a sub-optimal DAA regimen, 19 with a simeprevir-based regimen and 39 with an optimal DAA regimen. A major RAS was identified more frequently in the simeprevir regimen group (68.4%) and in the optimal regimen group (74.4%) than in the sub-optimal regimen group (56.3%). The prevalence of RASs in NS3 was similar in the three groups (30.8-57.9%), that in NS5A higher in the optimal regimen group (71.8%) than in the sub-optimal regimen group (12.5%, P < 0.0001) and in the simeprevir regimen group (31.6%, P < 0.0005), and that in NS5B low in all groups (0-25%). RASs in two or more HCV regions were more frequently identified in the optimal regimen group (46.6%) than in the simeprevir-based regimen group (31.6%) and sub-optimal regimen group (18.7%). In our real-life population the prevalence of RASs was high, especially in NS3 and NS5A and in those treated with suitable DAA regimens.

show abstract

Section: Introductionmentioning

confidence: 99%

Virological patterns of HCV patients with failure to interferon‐free regimens

Starace

Minichini

Pascalis

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In 2011, the directly acting antivirals (DAAs) NS3/4A protease inhibitors telaprevir and boceprevir were approved to treat HCV‐genotype‐1 infection, each in triple combination with Peg‐IFN and RBV [Jacobson et al, ; Poordad et al, ; Coppola et al, ]. This triple therapy achieved a 70% SVR in CHC patients with HCV‐genotype 1, but was characterized by a low tolerability and a high pill burden.…”

Section: Introductionmentioning

confidence: 99%

Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals

Coppola

Minichini

Starace

et al. 2016

Journal of Medical Virology

View full text Add to dashboard Cite

Introduced in 2013-2014, the second- and third-wave directly acting antivirals (DAAs) have strongly enhanced the efficacy and tolerability of anti-HCV treatment, with a sustained virological response (SVR) in 90-95% of cases treated. The majority of patients who did not achieve an SVR were found to be infected with HCV strains with a reduced susceptibility to these drugs. Indeed, the high error rate of the viral polymerase and a fast virion production (100-fold higher than the human immunodeficiency virus) result in a mixture of viral genetic populations (quasi-species) pre-existing treatment initiation. These mutants occur frequently in the NS5A region, with a moderate frequency in the NS3/4A region and rarely in the NS5B region. Treatment-induced resistant mutants to NS5A DAAs persist for years after treatment discontinuation, whereas those resistant to the NS3 DAAs have a shorter duration. This review focuses on the type and prevalence of viral strains with a reduced sensitivity to DAAs, their clinical impact and influence on the response to treatment and, consequently, on treatment choice for DAA-experienced patients. J. Med. Virol. 88:1659-1671, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

“…The response rate however, may vary from population to population in different demographic regions. Recent addition of the direct acting antivirals protease inhibitors, telaprevir and boseprevir to pegylated interferon, and ribavirin regimen as triple therapy has enhanced sustained virological response rate for HCV genotype 1 patients [Coppola et al, ]. Due to side effects and cost of different HCV regimens, several studies have been conducted to identify host and viral determinants for predicting the treatment response [Venegas et al, ] .…”

Section: Introductionmentioning

confidence: 99%

IL28Brs12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C

Waryah

Devrajani

et al. 2015

J. Med. Virol.

View full text Add to dashboard Cite

The aim of this study was to describe the genetic characteristics of Pakistani patients infected with hepatitis C virus (HCV) in relation to IL28B polymorphisms and its association to interferon and ribavirin treatment response. A total of 220 patients, infected with HCV were enrolled, out of which 100 were responders and 120 were nonresponders. The whole blood samples were collected to extract viral RNA and genomic DNA. PCR following the restriction fragment length polymorphism method was used to genotype IL28B rs12979860, rs8099917, and rs12980275 polymorphisms. Liver biopsies and HCV genotyping were performed in nonresponder patients. The rs12980275 AA genotype exhibited significant correlation to treatment response and was found in 62% of the responders and 37.5% of nonresponder patients, whereas AG genotype was noticed frequently in the nonresponder group (P < 0.0001). The rs12979860 CT and rs8099917 TT genotypes were found in 74% and 66% of the responders as compared to 58.3% and 50.8% in nonresponder patients (P = 0.001 and P = 0.032) respectively. HCV 3a genotypes were detected in 50.8% of the nonresponder patients. No significant association was detected between liver biopsy findings and IL28B SNPs (P > 0.05). The results showed the significant association of rs12980275 polymorphism with treatment response in HCV patients followed by rs12979860 and rs8099917. This is the first report describing the association of rs12980275 with response to HCV treatment from Pakistan. These findings may help in predicting the outcome of pegylated interferon and ribavirin treatment in HCV patients, and may reduce the side effects and cost of treatment in predicting non-responder patients.

show abstract

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on role of response predictors

Cited by 9 publications

References 37 publications

Virological patterns of HCV patients with failure to interferon‐free regimens

Virological patterns of HCV patients with failure to interferon‐free regimens

Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals

IL28Brs12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C

Contact Info

Product

Resources

About